Loading...

MGX METAGENOMI THERAPEUTICS INC Capital Structure Changes 8-K Filing

MTGN

MGX

METAGENOMI THERAPEUTICS INC

(MGX)

2025 8-K

Financial Results Update

Name Change Announcement

Financial Update

License Agreement Signed

Product Expansion

Financial Statements

Financial Results

Board Appointment

Data Presentation

Financial Results

Gene Therapy Update

External Links:

On March 17, 2025, Metagenomi Inc. entered into an agreement with Jefferies LLC to potentially sell up to $75 million of its common stock at its discretion. Jefferies will act as the sales agent, earning a commission of up to 3% on sales made.

AI Assistant

METAGENOMI THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.